October 26, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Share:
Kissei Pharmaceutical Obtains Manufacturing Approval for URIEF Capsule, Benign Prosatic Hypertrophy Drug
 

Tokyo, Jan 24, 2006 (JCN) - Kissei Pharmaceutical announced on January 23 that it has received approval from the Ministry of Health, Labor and Welfare to manufacture URIEF Capsule 2mg/4mg, its proprietary agent for treating benign prostatic hypertrophy (BPH).

URIEF Capsule (silodosin), a selective alpha-1A receptor antagonist, is indicated for the treatment of urinary disturbance associated with BPH.

After listing the drug on the NHI drug price list, Kissei Pharmaceutical and Daiichi Pharmaceutical will jointly promote the agent.

By Aki Tsukioka Contributor

Copyright © 2014 JCN. All rights reserved. A division of Japan Corporate News Network KK.


 Company Profile |   Print  |   Alerts
ACN Newswire

 Recent  Kissei Pharmaceutical  News  
  Kissei Announces New Drug Application for Silodosin has been Filed with FDA  (Feb 13, 2008)
  Kissei Enters Partners with Pneuma Partners LLC on Calfactant  (Jan 15, 2008)
  Kissei and Eisai Sign License Agreement to Develop and Commercialize Glufast(R), a Rapid-acting Insulin Secretagogue in China  (Sept 28, 2007)
  Kissei, Nuon Therapeutics Enter Agreement on Transilast  (Aug 1, 2007)
  Kissei and Eisai Sign a License Agreement to Develop and Commercialize Glufast(R), a Rapid-acting Insulin Secretagogue in 10 ASEAN Countries  (June 12, 2007)
  Kissei Pharmaceutical, Daiichi Pharmaceutical Jointly Launch Urination Disorder Improving Drug  (May 11, 2006)
  Kissei Pharmaceutical to License KGA, Diabetes Drug Candidate, to GlaxoSmithKline  (Apr 8, 2006)
  Kissei Pharmaceutical Obtains Manufacturing Approval for URIEF Capsule, Benign Prosatic Hypertrophy Drug  (Jan 24, 2006)
  Kissei Pharmaceutical, JCR Pharmaceuticals Enter into Joint Research Agreement for JR-013, Recombinant Human Erythropoietin-based Renal Anemia Agent  (Dec 27, 2005)
  Kissei Pharmaceutical, Dainippon Pharmaceutical Conclude Licensing Agreement for KGA-2727 Diabetes Drug Candidate  (Mar 17, 2005)



 Recent  Drugs & OTC News   
Otsuka's 'QuickNavi-Flu' Diagnostic Kit to Provide Additional Diagnosis-Related Information (Oct 14, 2014)
Nitto Denko Anti-fibrosis Drug Starts Phase-1b Dosing for Cirrhosis Patients in the US (Oct 10, 2014)
Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Yokogawa Technology Selected for JSTA's Next-generation Technology Transfer Program (Aug 8, 2014)
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation (Apr 24, 2014)
Kaneka, RIKEN Synthesize Bioplastic from Non-food Plant Resources
 (Apr 14, 2014)
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)
Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S. (Oct 10, 2013)

More Drugs & OTC news...

 Recent  Drugs & OTC News   
Otsuka's 'QuickNavi-Flu' Diagnostic Kit to Provide Additional Diagnosis-Related Information (Oct 14, 2014)
Nitto Denko Anti-fibrosis Drug Starts Phase-1b Dosing for Cirrhosis Patients in the US (Oct 10, 2014)
Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Yokogawa Technology Selected for JSTA's Next-generation Technology Transfer Program (Aug 8, 2014)
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation (Apr 24, 2014)
Kaneka, RIKEN Synthesize Bioplastic from Non-food Plant Resources
 (Apr 14, 2014)
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)
Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S. (Oct 10, 2013)

More Drugs & OTC news...
 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)